PSYCHOPHARMACOLOGICAL DRUGS ADVISORY COMMITTEE

November 3, 1999

Slides

Food and Drug Administration

Thomas Laughren, MD

Eli Lilly and Company

Disclaimer

The statements contained in this document are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Fluoxetine in the Treatment of PMDD, Gregory T. Brophy PhD